POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

NCT04826016 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funder decision

Conditions

Advanced Breast Cancer

Interventions

DRUG: POL6326
DRUG: Eribulin
DRUG: Nab paclitaxel

Sponsor

MedSIR